

해외 바이오의약품 임상 현황 ('22년 10월 4주)

한국바이오의약품협회, 2022.11.01.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
NCT number를 클릭하시면 세부 정보 페이지로 연결됩니다.
- 출처: ClinicalTrials.gov
- 모니터링 기간: 2022.10.24. ~ 2022.10.30.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 8건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT04527224	Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia	Drug: AstroStem-V	Nature Cell Co. Ltd.	Phase 1 Phase 2	https://ClinicalTrials.gov/show/NCT04527224
NCT05498220	Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma	Drug: Polatuzumab vedotin (PV) Drug: Rituximab Drug: Hyaluronidase Drug: Gemcitabine Drug: Cisplatin Drug: Dexamethasone Drug: GCSF	UNC Lineberger Comprehensive Cancer Center Genentech, Inc.	Phase 2	https://ClinicalTrials.gov/show/NCT05498220
NCT05410418	Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma	Drug: Mosunetuzumab Drug: Polatuzumab vedotin	Washington University School of Medicine Genentech, Inc.	Phase 2	https://ClinicalTrials.gov/show/NCT05410418
NCT05363709	A Phase 2 Study To Assess The Effect Of BALSTILIMAB (AGEN2034) On Viral Clearance In HPV-Positive Oropharyngeal Cancer Patients With Persistent HPV Detection In The Oral Rinse And/Or Plasma cfDNA After Definitive Therapy	Drug: Balstilimab	M.D. Anderson Cancer Center Agenus Inc.	Phase 2	https://ClinicalTrials.gov/show/NCT05363709
NCT04466475	Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melfalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma	Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Melfalan Procedure: Peripheral Blood Stem Cell Transplantation	Fred Hutchinson Cancer Center National Cancer Institute (NCI) National Institutes of Health (NIH)	Phase 1	https://ClinicalTrials.gov/show/NCT04466475
NCT05007418	Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma	Biological: STI-1492	Sorrento Therapeutics, Inc.	Phase 1	https://ClinicalTrials.gov/show/NCT05007418
NCT05552222	A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Teclistamab Drug: Daratumumab Drug: Lenalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	https://ClinicalTrials.gov/show/NCT05552222
NCT05271409	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease	Drug: Satralizumab Other: Placebo	Hoffmann-La Roche	Phase 3	https://ClinicalTrials.gov/show/NCT05271409

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05552222	A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Teclistamab Drug: Daratumumab Drug: Lenalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	https://ClinicalTrials.gov/show/NCT05552222

○ 프랑스 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05199688	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)	Drug: Satralizumab	Hoffmann-La Roche	Phase 3	https://ClinicalTrials.gov/show/NCT05199688
NCT05552222	A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Teclistamab Drug: Daratumumab Drug: Lenalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	https://ClinicalTrials.gov/show/NCT05552222

○ 독일 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05552222	A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Teclistamab Drug: Daratumumab Drug: Lenalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	https://ClinicalTrials.gov/show/NCT05552222
NCT05271409	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease	Drug: Satralizumab Other: Placebo	Hoffmann-La Roche	Phase 3	https://ClinicalTrials.gov/show/NCT05271409

해외 바이오의약품 임상 현황 ('22년 10월 4주)

한국바이오의약품협회, 2022.11.01.

○ 중국 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05596890	Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients	Drug: Paclitaxel-albumin Drug: Cisplatin Drug: Carboplatin Drug: Tislelizumab Radiation: VMAT or IMRT Procedure: Esophagectomy	Guangdong Provincial People's Hospital	Phase 2	https://ClinicalTrials.gov/show/NCT05596890
NCT05596266	CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia	Biological: CD5 CAR-T	Xuanwu Hospital, Beijing Baoding Children's Hospital	Phase 1	https://ClinicalTrials.gov/show/NCT05596266
NCT05522439	A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype	Drug: SHR-1703 Drug: SHR-1703 Placebo	Jiangsu HengRui Medicine Co., Ltd.	Phase 2	https://ClinicalTrials.gov/show/NCT05522439
NCT05514158	To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)	Drug: RC48-ADC Drug: RC98-ADC	RemeGen Co., Ltd.	Phase 1	https://ClinicalTrials.gov/show/NCT05514158
NCT05512598	HB0034 in Patients With Generalized Pustular Psoriasis (GPP)	Drug: HB0034	Shanghai Huaota Biopharmaceutical Co., Ltd.	Phase 1	https://ClinicalTrials.gov/show/NCT05512598
NCT05477927	Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases	Biological: Dual-targeting VEGFR1 and PD-L1 CAR-T cells	Sichuan University	Phase 1	https://ClinicalTrials.gov/show/NCT05477927
NCT05552222	A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Teclistamab Drug: Daratumumab Drug: Lenalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	https://ClinicalTrials.gov/show/NCT05552222

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05552222	A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Teclistamab Drug: Daratumumab Drug: Lenalidomide Drug: Dexamethasone	Janssen Research & Development, LLC	Phase 3	https://ClinicalTrials.gov/show/NCT05552222
NCT05271409	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease	Drug: Satralizumab Other: Placebo	Hoffmann-La Roche	Phase 3	https://ClinicalTrials.gov/show/NCT05271409